Free Trial
→ SpaceX will crumble without these 5 companies (From InvestPub) (Ad)tc pixel Free DMAC Stock Alerts

DiaMedica Therapeutics (DMAC) Competitors

DiaMedica Therapeutics logo
$5.72 +0.08 (+1.33%)
As of 10:00 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

DMAC vs. MPLT, CALT, COAG, AVLN, and WVE

Should you buy DiaMedica Therapeutics stock or one of its competitors? MarketBeat compares DiaMedica Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with DiaMedica Therapeutics include Maplight Therapeutics (MPLT), Calliditas Therapeutics AB (publ) (CALT), Hemab Therapeutics (COAG), Avalyn Pharma (AVLN), and WAVE Life Sciences (WVE). These companies are all part of the "pharmaceutical products" industry.

How does DiaMedica Therapeutics compare to Maplight Therapeutics?

Maplight Therapeutics (NASDAQ:MPLT) and DiaMedica Therapeutics (NASDAQ:DMAC) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, media sentiment, risk and earnings.

Maplight Therapeutics' return on equity of 0.00% beat DiaMedica Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Maplight TherapeuticsN/A N/A N/A
DiaMedica Therapeutics N/A -77.15%-69.23%

In the previous week, Maplight Therapeutics and Maplight Therapeutics both had 2 articles in the media. DiaMedica Therapeutics' average media sentiment score of 0.94 beat Maplight Therapeutics' score of 0.93 indicating that DiaMedica Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Maplight Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
DiaMedica Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Maplight Therapeutics currently has a consensus target price of $37.78, suggesting a potential upside of 35.08%. DiaMedica Therapeutics has a consensus target price of $12.33, suggesting a potential upside of 115.43%. Given DiaMedica Therapeutics' higher possible upside, analysts clearly believe DiaMedica Therapeutics is more favorable than Maplight Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Maplight Therapeutics
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
3 Strong Buy rating(s)
3.00
DiaMedica Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67

DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Maplight TherapeuticsN/AN/A-$161.15M-$40.99N/A
DiaMedica TherapeuticsN/AN/A-$32.77M-$0.71N/A

10.1% of DiaMedica Therapeutics shares are held by institutional investors. 3.8% of Maplight Therapeutics shares are held by company insiders. Comparatively, 5.0% of DiaMedica Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Maplight Therapeutics and DiaMedica Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does DiaMedica Therapeutics compare to Calliditas Therapeutics AB (publ)?

DiaMedica Therapeutics (NASDAQ:DMAC) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk and dividends.

10.1% of DiaMedica Therapeutics shares are owned by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. 5.0% of DiaMedica Therapeutics shares are owned by company insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, DiaMedica Therapeutics had 2 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 2 mentions for DiaMedica Therapeutics and 0 mentions for Calliditas Therapeutics AB (publ). DiaMedica Therapeutics' average media sentiment score of 0.94 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that DiaMedica Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
DiaMedica Therapeutics Positive
Calliditas Therapeutics AB (publ) Neutral

DiaMedica Therapeutics has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. DiaMedica Therapeutics' return on equity of -77.15% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company Net Margins Return on Equity Return on Assets
DiaMedica TherapeuticsN/A -77.15% -69.23%
Calliditas Therapeutics AB (publ) -30.18%-212.04%-27.96%

DiaMedica Therapeutics has higher earnings, but lower revenue than Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than DiaMedica Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DiaMedica TherapeuticsN/AN/A-$32.77M-$0.71N/A
Calliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85N/A

DiaMedica Therapeutics has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market.

DiaMedica Therapeutics presently has a consensus target price of $12.33, suggesting a potential upside of 115.43%. Given DiaMedica Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe DiaMedica Therapeutics is more favorable than Calliditas Therapeutics AB (publ).

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DiaMedica Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67
Calliditas Therapeutics AB (publ)
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

DiaMedica Therapeutics beats Calliditas Therapeutics AB (publ) on 12 of the 15 factors compared between the two stocks.

How does DiaMedica Therapeutics compare to Hemab Therapeutics?

DiaMedica Therapeutics (NASDAQ:DMAC) and Hemab Therapeutics (NASDAQ:COAG) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation, analyst recommendations and media sentiment.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DiaMedica TherapeuticsN/AN/A-$32.77M-$0.71N/A
Hemab TherapeuticsN/AN/AN/AN/AN/A

Hemab Therapeutics' return on equity of 0.00% beat DiaMedica Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
DiaMedica TherapeuticsN/A -77.15% -69.23%
Hemab Therapeutics N/A N/A N/A

DiaMedica Therapeutics currently has a consensus price target of $12.33, suggesting a potential upside of 115.43%. Hemab Therapeutics has a consensus price target of $41.75, suggesting a potential upside of 60.33%. Given DiaMedica Therapeutics' higher probable upside, equities research analysts plainly believe DiaMedica Therapeutics is more favorable than Hemab Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DiaMedica Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67
Hemab Therapeutics
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80

10.1% of DiaMedica Therapeutics shares are held by institutional investors. 5.0% of DiaMedica Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, DiaMedica Therapeutics and DiaMedica Therapeutics both had 2 articles in the media. DiaMedica Therapeutics' average media sentiment score of 0.94 beat Hemab Therapeutics' score of 0.93 indicating that DiaMedica Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
DiaMedica Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Hemab Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

DiaMedica Therapeutics beats Hemab Therapeutics on 5 of the 8 factors compared between the two stocks.

How does DiaMedica Therapeutics compare to Avalyn Pharma?

DiaMedica Therapeutics (NASDAQ:DMAC) and Avalyn Pharma (NASDAQ:AVLN) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk, earnings and dividends.

DiaMedica Therapeutics presently has a consensus target price of $12.33, indicating a potential upside of 115.43%. Avalyn Pharma has a consensus target price of $59.00, indicating a potential upside of 90.20%. Given DiaMedica Therapeutics' higher probable upside, research analysts clearly believe DiaMedica Therapeutics is more favorable than Avalyn Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DiaMedica Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67
Avalyn Pharma
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
2 Strong Buy rating(s)
3.20

Avalyn Pharma's return on equity of 0.00% beat DiaMedica Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
DiaMedica TherapeuticsN/A -77.15% -69.23%
Avalyn Pharma N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DiaMedica TherapeuticsN/AN/A-$32.77M-$0.71N/A
Avalyn PharmaN/AN/AN/AN/AN/A

In the previous week, DiaMedica Therapeutics and DiaMedica Therapeutics both had 2 articles in the media. DiaMedica Therapeutics' average media sentiment score of 0.94 beat Avalyn Pharma's score of 0.43 indicating that DiaMedica Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
DiaMedica Therapeutics Positive
Avalyn Pharma Neutral

10.1% of DiaMedica Therapeutics shares are owned by institutional investors. 5.0% of DiaMedica Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

DiaMedica Therapeutics beats Avalyn Pharma on 5 of the 9 factors compared between the two stocks.

How does DiaMedica Therapeutics compare to WAVE Life Sciences?

DiaMedica Therapeutics (NASDAQ:DMAC) and WAVE Life Sciences (NASDAQ:WVE) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends.

DiaMedica Therapeutics has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market. Comparatively, WAVE Life Sciences has a beta of -1.33, indicating that its stock price is 233% less volatile than the broader market.

DiaMedica Therapeutics has a net margin of 0.00% compared to WAVE Life Sciences' net margin of -255.70%. WAVE Life Sciences' return on equity of -56.76% beat DiaMedica Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
DiaMedica TherapeuticsN/A -77.15% -69.23%
WAVE Life Sciences -255.70%-56.76%-42.80%

In the previous week, WAVE Life Sciences had 5 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 7 mentions for WAVE Life Sciences and 2 mentions for DiaMedica Therapeutics. DiaMedica Therapeutics' average media sentiment score of 0.94 beat WAVE Life Sciences' score of 0.88 indicating that DiaMedica Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
DiaMedica Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
WAVE Life Sciences
1 Very Positive mention(s)
4 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

10.1% of DiaMedica Therapeutics shares are owned by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are owned by institutional investors. 5.0% of DiaMedica Therapeutics shares are owned by company insiders. Comparatively, 24.3% of WAVE Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

DiaMedica Therapeutics has higher earnings, but lower revenue than WAVE Life Sciences. DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than WAVE Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DiaMedica TherapeuticsN/AN/A-$32.77M-$0.71N/A
WAVE Life Sciences$42.73M26.68-$204.38M-$1.06N/A

DiaMedica Therapeutics currently has a consensus price target of $12.33, indicating a potential upside of 115.43%. WAVE Life Sciences has a consensus price target of $26.41, indicating a potential upside of 345.77%. Given WAVE Life Sciences' stronger consensus rating and higher probable upside, analysts plainly believe WAVE Life Sciences is more favorable than DiaMedica Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DiaMedica Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67
WAVE Life Sciences
1 Sell rating(s)
0 Hold rating(s)
14 Buy rating(s)
0 Strong Buy rating(s)
2.87

Summary

WAVE Life Sciences beats DiaMedica Therapeutics on 10 of the 15 factors compared between the two stocks.

Get DiaMedica Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for DMAC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DMAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DMAC vs. The Competition

Export
MetricDiaMedica TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$308.46M$3.39B$6.49B$12.05B
Dividend YieldN/A2.25%2.67%5.66%
P/E Ratio-8.0620.0524.0524.42
Price / SalesN/A325.48542.61123.88
Price / CashN/A53.6127.4837.92
Price / Book5.308.1610.696.82
Net Income-$32.77M$23.89M$3.57B$337.56M
7 Day Performance2.05%3.66%1.56%1.16%
1 Month Performance-5.53%1.69%2.49%3.16%
1 Year Performance56.85%46.95%26.51%30.60%

DiaMedica Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DMAC
DiaMedica Therapeutics
1.4807 of 5 stars		$5.73
+1.3%		$12.33
+115.4%		+54.8%$308.46MN/AN/A20
MPLT
Maplight Therapeutics
3.5151 of 5 stars		$28.01
-6.9%		$37.78
+34.9%		N/A$1.19BN/AN/A109
CALT
Calliditas Therapeutics AB (publ)
N/A$40.00
flat		N/AN/A$1.19B$1.60BN/A180
COAG
Hemab Therapeutics
4.5828 of 5 stars		$25.30
-0.4%		$41.75
+65.0%		N/A$1.18BN/AN/A72
AVLN
Avalyn Pharma
4.8502 of 5 stars		$27.06
+0.3%		$59.00
+118.0%		N/A$1.13BN/AN/A51

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:DMAC) was last updated on 6/15/2026 by MarketBeat.com Staff.
From Our Partners
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...
American Alternative | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Is SpaceX really worth 1.78 Trillion?
With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analy...
InvestPub | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
SpaceX is chump change compared to Elon’s $20T ‘iPhone’
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel